Kornimate/medical-research-clean huggingface dataset:
evaluation of the effect of coronavac vaccine (severe acute respiratory syndrome coronavirus 2 (sars-cov-2 vaccine) on healthcare workers' menstrual patterns

Conditions: Covid19; Vaccine Reaction; Coronavirus; Menstrual Problem; Endometrium

Summary: coronavac, one of the vaccines developed within the scope of combating the covid-19 pandemic that has surrounded the world for a year, started to be applied in the first healthcare workers in our country. in this important step taken to end the pandemic, information on vaccines is still limited. most vaccines, including the coronavac vaccine, are applied with approval for emergency use before phase 3 studies are fully completed. while investigating the effect of the vaccine on the virus, possible side effects should also be considered. in this context, it is not known whether the vaccine has an effect on the menstrual cycle, especially of women of reproductive age. our primary aim in our study is to evaluate the effect of the vaccine on the menstrual cycle and if the vaccine has any effect on the menstrual cycle, what kind of changes this effect causes.

the survey contains 20 questions aimed at obtaining information about the menstrual cycles of health workers before and after vaccination. demographic data of the participants are also taken.

Eligibility criteria:
inclusion criteria: * be positive for covid-19 (severe acute respiratory syndrome coronavirus 2 (sars-cov-2 ) * having 1 or 2 doses of vaccine * have menstruation * being a female health worker * not using drugs that can affect menstruation exclusion criteria: * be negative for covid-19(severe acute respiratory syndrome coronavirus 2 (sars-cov-2 ) * have no menstruation * being a male health worker
airseal®insufflation trocar/co2 absorption study

Conditions: Gynecologic Diseases

Summary: the purpose of this study is to compare carbon dioxide (co2) absorption during gynecologic laparoscopy using the airseal® valveless trocar system versus standard insufflation trocars at intra-abdominal pressures of 10 and 15 mmhg. the investigators hypothesize that with the airseal® valveless trocar system, gynecologic laparoscopy can be performed at a lower intra-abdominal pressure with a possible resultant decrease in co2 absorption, while maintaining adequate visualization of the operative field for safe completion of surgery.

three main factors affect patients' cardiopulmonary status during gynecologic laparoscopy: 1) degree of trendelenburg tilt (25 - 30°), 2) carbon dioxide (co2) absorption and 3) increased intra-abdominal pressure (10 -20 mmhg). slight modifications to any or all of these three factors can lead to a significant decrease in morbidity. the airseal® valveless trocar system reduces co2 absorption when compared to standard trocars during renal laparoscopy. also, use of this trocar system provides a more stable intra-abdominal pressure when compared to standard trocars, a feature that could possibly allow for laparoscopic surgery to be performed at lower intra-abdominal pressures.

Eligibility criteria:
inclusion criteria: * any woman ≥ 18 years of age undergoing a gynecologic laparoscopic procedure * able to understand the consenting process and willing to participate in study exclusion criteria: * patient unable to undergo laparoscopic procedure due to size of pathology or medical comorbidities * emergent surgery

Keywords: gynecology laparoscopy pneumoperitoneum co2 absorption
hyaluronan in embryo transfer media

Conditions: Infertility

Summary: prospective randomized double blind comparison of hyaluronan enriched embryotransfer media and conventional embryotransfer media in human ivf treatments. embryos selected for transfer are incubated in a culture media containing high concentration of hyaluronan or low concentration of hyaluronan. primary outcome: implantation and pregnancy rates


Eligibility criteria:
inclusion criteria: * infertile patients * entering in vitro fertilization treatment * at least 1 embryo transferred exclusion criteria: * ivf treatment with donated oocytes * no embryo available for transfer

Keywords: in vitro fertilization embryotransfer hyaluronan pregnancy rate implantation rate
effect of intraoperative anesthetic management on postoperative nausea and vomiting in bariatric surgery

Conditions: Postoperative Nausea and Vomiting

Summary: morbidly obese patients are at high risk for postoperative nausea and vomiting (ponv) after surgery and general anesthesia. the results of our observational study indicate that 42.7% of patients require medication to treat ponv in the first 24 hours after bariatric surgery despite our aggressive perioperative approach with triple prophylaxis. common risk factors for ponv are the use of intraoperative narcotics and anesthetic gases. preliminary results of multimodal postoperative analgesia in the first 24 hours lead to a reduction of narcotic consumption, desaturations and use of antiemetic medication. our study hypothesis is that different types of anesthetics reduce ponv further. patient would be randomly assigned to receive either our current intraoperative management or a narcotic free, total intravenous general anesthetic (tiva). the investigators hope to improve patients' satisfaction by reducing ponv in the postoperative period.

see above

Eligibility criteria:
inclusion criteria: * all patients scheduled for bariatric surgery at flagler hospital will be included after written and informed consent. exclusion criteria: * patients will be excluded from the study if they don't consent to participate in the study. patients allergic to any of the study medication will be excluded. patients with second or third degree heart block will be excluded.

Keywords: bariatric surgery tiva ponv non-opioid osa
the akloma tinnitus patch in patients with manifested tinnitus

Conditions: Tinnitus

Summary: objectives: primary objective the primary objective will be a decrease of inconvenience with at least 10% for at least 50% of the subjects. secondary objectives the secondary objective will be to: to evaluate if the patch can improve the tinnitus patient's quality of life and sleep quality. methodology study design: an open safety and performance clinical investigation of the antinitus patch in patients with manifested tinnitus. treatment duration: 1 patch per day for 3 weeks primary endpoint: tinnitus severity questionnaire (tsq) performance parameters: tinnitus severity questionnaire (tsq) and numerical rating scale (nrs) measuring tinnitus annoyance. quality of life and sleep quality safety parameters: adverse reactions


Eligibility criteria:
inclusion criteria: * adults of both sexes \> 18 years of age * signed informed consent * patients who have suffered from tinnitus for ≥ 4 weeks before study entry * manifested tinnitus grade ii or above on the klockhoff-lindblom tinnitus severity grading scale. * tinnitus score of 5 or above (numerical rating scale for tinnitus annoyance) * pure tone averages better than 40 db in the worse hearing ear. exclusion criteria: * pregnant or lactating women * malignancy or other serious medical conditions * skin disease * simultaneous or previous (within 30 days prior to study entry) participation in a clinical study using experimental drugs or devices. * severe psychiatric disorder * serious suicidal risk * patients who have started treatment or made changes in treatment with drugs known to influence tinnitus within 6 weeks before study start. * patients with untreated high blood pressure ≥140/90 mmhg * other tinnitus treatment within 6 weeks before study entry. * previous use of the antinitus patch * known allergy or sensitivity to any of the compounds in the antinitus or the placebo patches.
exercise for subacromial pain syndrome

Conditions: Subacromial Pain Syndrome

Summary: this study evaluates the effect of heavy slow resistance exercise (hsr) exercise in comparison with traditional supervised exercise as treatment for patients with subacromial shoulder pain. the purpose is to evaluate if hsr is feasible fir these patients, and compare its effect to traditional exercise at pain and function of the shoulder. one half will complete the heavy slow resistance exercise, the other will complete the conventional exercise.


Eligibility criteria:
inclusion criteria: * shoulder pain \> three months * subacromial pain * dysfunction or pain during abduction * pain during isometric strength test of abduction or external rotation of the shoulder. * positive hawkins test * normal passive range of movement in the glenohumeral joint exclusion criteria: * surgery of the affected shoulder * patients that are not considered suitable to complete the treatment, or able to answer a norwegian questionnaire * shoulder dislocation or shoulder instability * clinical sign of cervical nerve root affection * rheumatoid arthritis * clinical sign of full rupture of the rotator cuff. * pregnancy * cortisone injection past six weeks
a study to evaluate the impact of stopping treatment for the prevention of pneumonia in hiv-positive patients receiving anti-hiv drugs who have increased cd4 cell counts

Conditions: Pneumonia, Pneumocystis Carinii; HIV Infections

Summary: the purpose of this study is to see how often pneumocystis carinii pneumonia (pcp) occurs in hiv-positive patients who have stopped taking medications that help prevent pcp. the risk of developing pcp may be decreased when an hiv-positive patient's cd4 cell counts (cells of the immune system which fight infection) are more than 200 cells/mm3. this study looks at whether it is acceptable to stop pcp prevention treatment in these patients.

the risk of developing pcp may be decreased with treatment-induced recovery of cd4 counts to \> 200 cells/mm3. few data exist to confirm or negate the continued necessity of pcp prophylaxis for such patients. this study will assess the effects of discontinuing therapy. subjects are asked to discontinue pcp prophylaxis if antiretroviral therapy has resulted in a sustained cd4 increase greater than 200 cells/mm3 on two measurements at least 12 weeks apart. they will be evaluated for symptoms and cd4 counts every 8 weeks as well as plasma for hiv-rna every 16 weeks for 18 months. subjects whose cd4 count falls to less than 150 cells/mm3 or between 150 and 200 cells/mm3 will have the cd4 count re-evaluated immediately or within 4 weeks. if the second cd4 count is less than 200 cells/mm3 for either case, conventional pcp prophylaxis will be resumed and the subject will be followed on study. subjects will be followed during study by physical exams and laboratory tests at weeks 4, 8, and every 8 weeks thereafter.

Eligibility criteria:
inclusion criteria you may be eligible for this study if you: * are hiv-positive. * have had 1 cd4 cell count of less than 100 cells/mm3 and have never had pcp, or have had at least 2 cd4 cell counts over 200 cells/mm3 and have had pcp within 6 months prior to study entry. * have received pcp prevention medication within 3 months of study entry. * are at least 13 years old (need consent if under 18). * are taking anti-hiv (antiretroviral) medication at study entry. exclusion criteria you will not be eligible for this study if you: * have active pcp or symptoms of pcp within 2 weeks of study entry. * have a fever lasting more than 2 weeks. * have oral candidiasis (thrush).

Keywords: aids-related opportunistic infections pneumonia, pneumocystis carinii antiviral agents cd4 lymphocyte count rna, viral
cardiac safety of indacaterol

Conditions: Healthy Volunteers; Chronic Obstructive Pulmonary Disease

Summary: this study compares the cardiac safety of inhaled indacaterol with that of placebo and oral moxifloxacin.


Eligibility criteria:
inclusion criteria: * healthy, non-smoking * body mass index (bmi) 18.5-32 kg/m2 * body weight at least 50 kg exclusion criteria: * recent/concurrent use of concomitant medications (except acetaminophen) * recent participation in other clinical trials * recent donation or loss of blood * history/presence of a range of medical conditions, including electrocardiographic (ecg) abnormalities, diabetes mellitus, hyperthyroidism and impaired renal function other protocol-defined inclusion/exclusion criteria may apply

Keywords: indacaterol moxifloxacin
noninvasive brain stimulation in mild cognitive impairment and dementia

Conditions: Alzheimer Disease; Mild Cognitive Impairment; Dementia

Summary: the research objective of this study is to examine the efficacy of hd-tdcs to the presma/dacc region and its influence on verbal episodic memory in patients with mci or dementia after 10 sessions of hd-tdcs. there will be three treatment arms: two active hd-tdcs (1 ma or 2 ma) and a sham group. a verbal episodic memory task will be completed at baseline, immediately following the last hd-tdcs session, and a 2-month follow-up.

this is a pilot study being done to attempt to improve verbal episodic memory in persons with mild cognitive impairment (mci) and dementia. although the hippocampus is a brain structure most often associated with early deficits in mci and dementia, the pre-supplemental motor area (presma) and dorsal anterior cingulate cortex (dacc) have been shown to play a role in verbal episodic memory for such patients. the purpose of this study is to examine the efficacy of high-definition transcranial direct current stimulation (hd-tdcs) to the presma/dacc region and its influence on verbal episodic memory in patients with mci and dementia. entraining the presma/dacc circuit with 10 sessions at one of two levels of hd-tdcs will allow the researchers to investigate whether neuromodulation may be used to improve verbal episodic memory. participants will receive 10 sessions at one of two levels of active stimulation (1 ma or 2 ma anodal hd-tdcs targeting presma/dacc for 20 min) or sham across 2 weeks. the device is used to deliver high definition transcranial direct current stimulation to targeted regions. a verbal episodic memory task will be completed at baseline, immediately following the last hd-tdcs session, and a 2-month follow-up. the investigators plan to recruit english-speaking participants aged 50 years and older with mci and dementia. participants will be randomized into hd-tdcs conditions.

Eligibility criteria:
inclusion criteria: 1. age 50 and older 2. fluent in english 3. active diagnosis of mci or dementia exclusion criteria: 1. substance use disorder 2. has metal fragments in head 3. taking medications that may interact with the hd-tdcs effect (i.e., amphetamines, l-dopa, carbamazepine, sulpiride, pergolide, lorazepam, dextromethorphan, d-cycloserine, flunarizine, or ropinirole)

Keywords: transcranial direct current stimulation alzheimer disease mild cognitive impairment dementia mci mild neurocognitive disorder amnestic pre- alzheimer
serum interleukin 6 in chronic obstructive pulmonary disease

Conditions: Chronic Obstr Lung Disease

Summary: the aim of this study is to estimate level of il 6 in copd patients and its relation to copd severity and acute exacerbation.

1. a detailed clinical history was be carried out for every patient. in the clinical history, duration of copd with a history of exacerbation and treatment will be elicited. history of the presence of risk factors such as smoking, exposure to fumes (biomass), and the presence of any other chronic disease were be inquired. 2. thereafter, the detailed physical examination also had been carried out. 3. pulmonary function test was performed by master screen no : 781040 (care fusion) measurements were obtained for fvc,fev1,ratio between them, pef,fef25%,fef50% ,and fef75% (the readings for fev1 and ratio were the ones included in the statistical analysis as indices for obstructive pattern of respiration). 4. labs including complete blood count, urea, and serum creatinine ,esr was done for all patients 5. exercise capacity by six minutes' walk test. 6. dyspnea score by mmrc score. 7. health state assessment by cat score 3- 8- determination of il 6 serum levels. by sandwich enzyme-linked immunosorbent assay (elisa). the detection range (0.2 ng/l- 8ng/l)

Eligibility criteria:
inclusion criteria: 1. all patients aged \>40 years and \<80 years, of both gender 2. diagnosed to have copd according to gold 2019 by spirometry 3. given the consent for participation in the study exclusion criteria: 1- any patient with systemic inflammation as 1. bronchial asthma, 2. rheumatoid arthritis.
hypofractionated radiotherapy in prostate cancer patients aged 75 years or older.

Conditions: Prostate Cancer; Radiotherapy Side Effect

Summary: the majority of all new prostate cancer cases are diagnosed in men aged \> 70 years, with the highest incidence in men aged \> 90 years. management options for localized prostate cancer include active surveillance in patients with low-risk disease, radical prostatectomy or external beam radiation therapy. in previous studies, hypofractionated prostate cancer irradiation regimens have been shown to represent a highly effective treatment option for prostate cancer. however, patients aged 75 years or older were underrepresented in most trials resulting in the lack of a robust evidence base. the proposed study will evaluate radiation-induced toxicity as well as outcome after hypofractionated external beam radiotherapy in prostate cancer patients aged 75 years or older.


Eligibility criteria:
inclusion criteria: * histologically confirmed prostate cancer adenocarcinoma * definitive radiotherapy for curative intent * low or intermediate risk prostate cancer * patient age ≥ 75 years * given informed consent exclusion criteria: * chronic inflammatory bowel disease * high risk prostate cancer * lymph node or distant metastases * unable to give informed consent

Keywords: hypofractionated radiotherapy
quantifying quadriceps atrophy following tibial plateau fracture

Conditions: Atrophy

Summary: this study will quantify and examine the extent to which the quadriceps femoris muscle group atrophies following tibial plateau fractures and the length of time that atrophy affects function. the study will also look at the effects of tibial plateau fractures on the quadriceps muscle and the effect this atrophy has on functional outcome. quadriceps atrophy will be measured both clinically and by using mri scans taken pre-operatively, 3 months post operatively, and 1 year post-operatively. the injured leg and the non-injured leg will be scanned in order for the non-injured leg to serve as the control. in this way muscle volume can be estimated from the muscle thickness at specific locations in the thigh. the muscle strength of the quadriceps will also be assessed at the 3 month and 1 year visit by measuring isokinetic knee-extension torque, and functional assessment questionnaires will be completed at each study visit.


Eligibility criteria:
inclusion criteria: * all racial and ethnic groups * diagnosis of tibial plateau fracture * patients who opt for surgical treatment or non-operative treatment of their fracture * patients who consent to undergoing 3 mri scans * patients who are willing to follow-up for a minimum of 52 weeks exclusion criteria: * patients younger than 18 years old or older than 65 * patients who may be pregnant or may become pregnant in the 52 weeks following injury * patients who have electric, magnetic, or mechanical devices currently implanted * patients who have abnormal ecg results * diagnosis of any additional lower extremity fractures other than tibial plateau * patients who fit the definition of a vulnerable population

Keywords: quadriceps tibial plateau fracture
early diagnosis, pathogenesis and progression of open angle glaucoma

Conditions: Primary Open Angle Glaucoma; Secondary Open Angle Glaucoma; Ocular Hypertension

Summary: the erlangen glaucoma registry is a clinical registry for cross sectional and longitudinal observation of patients with open angle glaucoma (oag) or glaucoma suspect, founded in 1991. the primary aim is the evaluation of diagnostic and prognostic validity of morphometrical, sensory and hemodynamical diagnostic procedures. no therapeutic studies are performed.

purpose: detection of onset and progression of structural and functional damage due to glaucoma. determination of rate and amount of progressive change due to glaucoma. characterisation of the relationship between structural and functional change over time. evaluation of predictive factors for the development and progression of glaucoma.

Eligibility criteria:
participants: * patients: primary open angle glaucoma, secondary open angle glaucoma due to pex or mds, glaucoma suspects including ocular hypertension * healthy volunteers (for cross sectional analysis only) inclusion criteria: * open anterior chamber angle * best corrected visual acuity 0.7 or better * age between 18 and 65 years exclusion criteria: * any eye disease other than glaucoma * systemic diseases with potentially ocular involvement (e.g., diabetes mellitus) * myopic or hyperopic refractive error exceeding 8.0 diopters
outcome following phacoemulsification versus small incision cataract surgery (sics)

Conditions: Visual Outcomes; Quality of Life

Summary: hypothesis : phacoemulsification is superior to sics with regards to: * immediate unaided high and low contrast visual performance * its impact on quality of life.

phacoemulsification procedure * infiniti vision system with software 2.03 or higher, ozil handpiece (hp) * anaesthesia: topical * incision: temporal clear corneal 2.2 mm single plane * ccc and hydrodissection, sculpting and division using step by step chop in situ and lateral separation, i/a. * single-piece acrysof iol (sn60wf) in the bag sics procedure * anaesthesia: peribulbar * incision: superior scleral tunnel 6.5 to 7 mm * ccc and hydrodissection * nuclear expression: blumenthal technique using anterior chamber maintainer, manual cortical clean-up * single-piece pmma (mz60bd) in the bag

Eligibility criteria:
inclusion criteria: * prospective subjects should be diagnosed with senile cataract. subject must require extraction of cataract in one eye followed by implantation of an acrysof (sn60wf) or pmma (mz60bd) posterior chamber intraocular lens. * pupil dilation equal or greater to 7 mm after mydriasis. * patients undergoing cataract surgery for the first eye. * visual prognosis equal or greater to 6/12. exclusion criteria: * patients with history of ocular pathology, glaucoma, uveitis, high myopia, pex, or corneal pathology. * patients with traumatic, subluxated and posterior polar cataract. * patients who had previously ocular surgery in the past 6 months prior to the screening visit. * patients with diabetic retinopathy. * patients who are not suitable for follow-up visits. * patients with fuchs' dystrophy, macular degeneration, ocular surface disease that will interfere with normal recovery. * any patients with significant intra-operative complications will be removed from the overall analysis of the results. all patient data should still be recorded, even if from the "excluded" patient group.

Keywords: phacoemulsification manual small incision cataract surgery visual acuity contrast sensitivity quality of vision